database > company
Stage I Diagnostics
HCID Member | Medical Devices & Tech
4301 West Markham, #831
Little Rock, AR 72205 USA
phone:(501) 686-6696
fax:
Symbol Private
Founded 2005
Employees 5
          www.Stage1Diagnostics.com
Research Sector Medical Devices & Tech
Summary Description
Develops and markets diagnostic products to detect ovarian, prostate and other reproductive tract cancers at their earliest stages.
Management
Dr. Tim O'Brien, Chairman & Co-Founder; John Beard, Production Manager; Dr. Mary Good, Director; Mr. H. Watt Gregory, III, Director Partner, Kutak Rock LLP; Mr. Michael Higgins Director/ Investor; Mr. Gregory E. Gardner, Ph.D., Ms. Denise Rose
Keywords
Immunoassay Segment, fusion, ovarian cancer, breast cancer, cancer, prostate, reproductive tract cancer, idiagnostics

Comment | Printable Version | Modify profile Aug. 22, 2009

Description
Stage I's initial focus is on the early detection of ovarian, prostate and other cancers of the reproductive tract and pancreatic and breast cancer.
Products / Services
The current status of the 8 antibodies planned for the multiple tumor marker panel is below:

TADG-14
Existing panel of antibodies (8 to E. coli recombinant)
7 new antibodies in validation (insect recombinant)
ALP
1 existing antibody from insect recombinant (purified)
4 new antibodies from IPA fusion (fusion 1)
7 new antibodies from ProMab fusion (fusion 2)
TADG-15
1 existing antibody from E. coli recombinant (purified)
9 new antibodies from IPA fusions (fusion 1)
4 new antibodies from ProMab fusions (fusion 2)
SCCE
2 new antibodies from IPA fusion (fusion 1) (insect recombinant)
2nd fusion pending (ProMab)
3rd fusion planned if necessary in January 2009 (ProMab)
MMP-7
1 new antibody from IPA fusion (fusion 1) (insect recombinant)
2nd fusion week of 11/24 at ProMab
3rd fusion planned if necessary in January 2009 (ProMab)
Hepsin
1 existing antibody from E. coli recombinant (purified)
2 fusions pending:
  • Harlan ID model, screening in January 2009
  • ProMab sub-cute model, screening in December 2008

    • TADG-12/12D
    10 antibodies from E. coli recombinant fusions
    Awaiting new antigen for new fusions
    Protease M
    Fusion 1 just completed
    Back-up fusion 2 if necessary
    Technology / Differentiation
    The Company's proprietary technology, under exclusive worldwide license from the University of Arkansas for Medical Sciences ("UAMS"), is based on the identification of tumor-associated proteases, protease inhibitors, and related substances.

    Using a diagnostic panel approach we are able to detect early-stage disease where current testing can't and do it at a higher sensitivity and specificity than current methods.
    Market / Customers
    laboratories and research institutes that specialize in cancers of the reproductive tract. there is no reliable diagnostic tool available to detect ovarian cancer in its early stage, and it is most frequently detected in its latter stages when effective treatment is more difficult.
    Competitors / Substitutes / Alternatives
    Any diagnostic entity offering diagnostics based on CA125 and/or any diagnostic enterprise seeking to enhance CA125 with additional antibodies such as HE4.
    Strategy
    Our business strategy is based on the development of two different product lines. The two product lines will be developed and introduced in phases. The first phase will involve our first product line: reagents (antibodies and antigens). This will enable us to generate revenues at an earlier stage than otherwise possible for a company planning to make and sell diagnostic test systems, and will help fund the development costs for those systems. The second phase, and main focus of the Company, will be dedicated to branded SOC diagnostic and monitoring systems.
    Status
    The worldwide diagnostics market represented $21 billion in total sales revenues in 2000. Industry sources project the annual growth rate at approximately 5%. Of that total market, Stage I is concentrated on the Immunoassay Segment which had year 2000 revenues of $7.2 billion. The oncology portion of this segment that is currently available to Stage I conservatively represents about $500 million in sales revenues.
    The U.S. ovarian cancer test market alone has an estimated annual potential of $3.3 billion.
    For prostate cancer, a reliable test could replace or add to prostate specific antigen (PSA) as the marker of choice. The U.S. prostate cancer test market has an estimated annual potential of $929 million.
    The home testing market represented about $1.9 billion in sales in 1998. The market was estimated to reach $3.5 billion in sales in 2004. This market is growing at an annual rate of about 10%.
    Additional Information
  • UAMS BioVentures Business Incubator-UAMS BioVentures provides client companies significant development support.


    • 2010-09-01-927